(lp0
S'Supernus Pharmaceuticals: The Investment Case Improves Seeking Alpha - Dec 15, 2016 Tier 2 biotech concern Supernus Pharmaceuticals received some good news regarding key patent litigation this week. This the latest piece of positive news for ... This removes an overhang from the company and the stock. Oxtellar XR is the lesser of two ...'
p1
aS'Supernus Pharmaceuticals Offers A Rare Opportunity For Investors Seeking Alpha - Jan 5, 2017 Supernus Pharmaceuticals  is a rarity among the thousands of publicly-traded biotechnology firms; it has approved products, revenue and earnings.'
p2
aS'Supernus: Label Expansion, Trokendi Settlement Catalysts For More Upside Seeking Alpha - Mar 16, 2017 The company guided for 2017 sales in the $265-275 million range, which is right in line with my estimate range for the year.'
p3
aS'Supernus Is Moving In The Right Direction Seeking Alpha - Jan 26, 2017 Supernus Is Moving In The Right Direction ... The marketed product portfolio continues to grow at a healthy pace and the company is on its way to becoming significantly profitable in 2017 considering the growing revenues and solid operating leverage.'
p4
aS'Juncture Wealth Strategies LLC Has $1.611 Million Stake in Supernus ... The Cerbat Gem - 12 hours ago Supernus Pharmaceuticals logo Juncture Wealth Strategies LLC increased its stake in Supernus Pharmaceuticals Inc  by 0.8% during the first quarter, according to its most recent Form 13F filing with the SEC.Supernus Pharmaceuticals Inc  Given Consensus Recommendation of &quot;Buy&quot; by ... - BBNSAnalyst Views And Outlook On Two Stocks: Supernus Pharmaceuticals, Inc. (SUPN ... - Post Analyst'
p5
aS'Commit To Purchase Supernus Pharmaceuticals At $26, Earn 15.3% Annualized ... Nasdaq - Apr 7, 2017 Investors considering a purchase of Supernus Pharmaceuticals Inc  stock, but cautious about paying the going market price of $30.10/share, might benefit from considering selling puts among the alternative strategies at their disposal.'
p6
aS"Supernus Pharmaceuticals'  CEO Jack Khattar on Q3 2016 Results ... Seeking Alpha - Nov 18, 2016 Good morning everyone, and thank you for joining us today for Supernus Pharmaceuticals' third quarter 2016 business update conference call."
p7
aS'Is Supernus Accurately Evaluating The Market Opportunity? Seeking Alpha - Nov 28, 2016 Supernus Pharmaceuticals  was supposed to release its results for the three months ended September 30, 2016, in late November.'
p8
aS'Supernus Receives Final FDA Approval for Trokendi XR for Migraine Prophylaxis ... GlobeNewswire  - Apr 5, 2017 ROCKVILLE, Md., April 05, 2017  -- Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today&nbsp;...'
p9
aS'Supernus - SPN-812 Results And Thesis Update Seeking Alpha - Oct 14, 2016 The study met its primary endpoint and the effect size was really good for a non-stimulant product. The results support the case for SPN-812 being the dominant non-stimulant product in the ADHD market.'
p10
a.